EUVIMEDEUVIMED entdecken
Crossref

EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025)

Christopher Daly, Jeromie Ballreich

Value in Health · 2026-06 · 29 (6) · S139

DOI: 10.1016/j.jval.2026.03.694 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2026-06. Verfasst von Christopher Daly und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Daly, C., & Ballreich, J. (2026). EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025). Value in Health, 29(6), S139. https://doi.org/10.1016/j.jval.2026.03.694

Vancouver

Daly C, Ballreich J. EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025). Value in Health. 2026;29(6):S139. doi:10.1016/j.jval.2026.03.694

BibTeX
@article{Daly2026,
  author = {Daly, Christopher and Ballreich, Jeromie},
  title = {EE400 ADALIMUMAB BIOSIMILAR UPTAKE IN US MEDICAID: AN ANALYSIS OF MANAGED CARE VS. FEE-FOR-SERVICE EXPENDITURE TRENDS (2024-2025)},
  journal = {Value in Health},
  year = {2026},
  volume = {29},
  number = {6},
  pages = {S139},
  doi = {10.1016/j.jval.2026.03.694}
}
Kostenlos starten →